Breast cancer screening, what the guidelines actually say

A screening test can only help if it starts early enough to matter and stops once the evidence runs out, and breast cancer screening is a case where the U.S. Preventive Services Task Force moved that starting line in 2024. This page summarizes the current guidance, why it changed, and where it still leaves an open question.

What this screening is and what it looks for

Breast cancer screening looks for cancer in breast tissue before it causes a lump or any other symptom a person would notice on their own. The tool the USPSTF evaluated is mammography, an X-ray image of the breast, including newer digital breast tomosynthesis (sometimes called 3D mammography). Mammography does not diagnose cancer by itself; a suspicious finding leads to additional imaging and, often, a biopsy to confirm what it is.

Screening mammography is aimed at people without symptoms and without a known high risk of breast cancer. It is a different question from diagnostic imaging ordered because someone has already found a lump or has symptoms, which is evaluated on its own timeline regardless of any screening schedule.

Who and when, per the USPSTF

In its 2024 recommendation, the USPSTF sets a single band for most of its recommended population:

• Ages 40 to 74: Grade B. The Task Force recommends biennial (every 2 years) screening mammography. This applies to cisgender women and other people assigned female at birth, including transgender men and nonbinary people, at average risk, and it explicitly includes people with a family history of breast cancer or with dense breasts, not only a narrowly defined “average risk” group.
• Age 75 and older: Grade I. The Task Force found the current evidence insufficient to weigh the balance of benefits and harms in this age group and did not issue a for-or-against recommendation.
• Supplemental screening for dense breasts: Grade I. For a person with dense breasts and an otherwise negative mammogram, the evidence on whether additional ultrasound or MRI does more good than harm is, again, insufficient in the Task Force’s assessment.

People with a genetic marker or syndrome linked to high risk (such as a BRCA1 or BRCA2 variant), a history of high-dose chest radiation at a young age, or a personal history of breast cancer or a high-risk biopsy result are outside the scope of this recommendation; they are generally managed with a different, individualized screening plan.

These bands describe guideline eligibility and the strength of the evidence behind it, not an instruction that any particular person should be screened on a particular date. Timing and any individual adjustment is a conversation with a clinician who knows a person’s history.

The evidence and its grade

The 2024 change was not a reversal from scratch; it built on and extended the Task Force’s long-standing 50-to-74 recommendation. Before 2024, the USPSTF gave ages 50 to 74 a Grade B and treated ages 40 to 49 separately at Grade C, meaning the decision to start screening before 50 was left as an individual one rather than a routine recommendation. The 2024 update raised that 40-to-49 band to Grade B as well, folding it into one continuous 40-to-74 recommendation.

The Task Force describes its overall conclusion as moderate certainty that biennial mammography in this population has a moderate net benefit, the same certainty language used for the prior 50-to-74 recommendation, now extended to the newly added decade. Two things drove the change, by the Task Force’s own account: data showing breast cancer incidence in women in their 40s increased more noticeably between 2015 and 2019 than in the years before, and modeling evidence that starting at 40 could narrow the mortality gap facing Black women, who are about 40% more likely to die of breast cancer than White women despite a similar or lower incidence rate. As with any modeling-supported change, this rests on a different kind of evidence than a completed randomized trial with mortality endpoints, which is part of why the certainty is described as moderate rather than high.

Where the guidance differs

The American Cancer Society welcomed the 2024 USPSTF change but its own guideline was already ahead of it and still is not identical. ACS gives women the option to start annual mammography at 40, treats annual screening starting at 45 as its regular recommendation, and lets women 55 and older choose to continue yearly screening or switch to every other year, rather than defaulting everyone to a 2-year interval the way the USPSTF does. ACS has also said publicly that it is disappointed the USPSTF stops its recommendation at age 74, arguing that anyone with a life expectancy of 10 years or more, regardless of age, should not be considered to have aged out of screening. Neither position is settled science; they are two organizations weighing the same limited trial evidence, particularly for the newer 40-to-49 band and for people past 74, differently. The Grade I on supplemental screening for dense breasts is its own open question: many states require that patients be notified about breast density, but the USPSTF is explicit that it does not yet have enough evidence to say whether follow-up imaging in that situation helps more than it harms.

Questions to ask your clinician

Framed as questions to bring to a visit, not as steps to take on your own:

• Given my age and family history, does the 40-to-74 Grade B population describe me, or do I have a risk factor that puts me on a different, individualized screening plan?
• The USPSTF recommends every 2 years; how should I think about ACS’s option for annual screening, and does that choice matter for someone like me?
• I have dense breast tissue; what does that mean for how well a mammogram works for me, and is supplemental imaging something worth discussing given the evidence is still unsettled?
• I am nearing or past 74; how should I weigh continuing screening when the Task Force says the evidence there is insufficient rather than favorable or unfavorable?
• What actually happens if a mammogram finds something, and how is that different from a screening result versus a diagnosis?

You can compare this profile against the full Guideline Tracker, read the sibling profiles for cervical cancer screening and colorectal cancer screening, or see how everyday choices fit alongside screening in the big levers.